|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Burstein HJ. The distinctive nature of HER2-positive breast cancer. N Engl J Med 2005;353(16):1652-4. No abstract available
Buzdar AU. Topoisomerase II alpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. J Clin Oncol 2006;24(16):2409-11. No abstract available
De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;16(Suppl 4):iv7-iv13. Abstract
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365(9472):1687-717. Abstract
Kim C et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 46.
Koziner B et al. Pooled safety analysis of oblimersen alone or with fludarabine and cyclophosphamide in patients with advanced chronic lymphocytic leukemia. Proc ASCO 2006;Abstract 6611.
Lippman ME et al. The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 1978;298(22):1223-8. Abstract
Mohsin SK et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23(11):2460-8. Abstract
Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Poster 1045.
Scandinavian Breast Group Trial 9401. Topoisomerase II alpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol 2006;24(16):2428-36. Abstract
Slamon D et al, on behalf of the BCIRG 006 Investigators. Phase III randomized trial
comparing doxorubicin and cyclophosphamide followed by docetaxel (AC
T) with
doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast
cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium
2005;Abstract 1.
Villman K et al. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer. Acta Oncol 2006;45(5):590-6. Abstract
 |
 |
Editor’s Note:
Reality check
Interviews
Marc E Lippman, MD
- Select publications
C Kent Osborne, MD
- Select publications
I Craig Henderson, MD
- Select publications
Charles E Geyer Jr, MD
- Select publications
Frank A Vicini, MD
- Select publications
Miami Beach Cancer Conference Tumor Panel Discussion on Systemic Therapy of Metastatic Disease
- Select publications
 |
 |
 |
 |
 |
